These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292 [TBL] [Abstract][Full Text] [Related]
4. [Comparison of Preferential Hyperacuity Perimeter (PHP) test and Amsler grid test in the diagnosis of different stages of age-related macular degeneration]. Kampmeier J; Zorn MM; Lang GK; Botros YT; Lang GE Klin Monbl Augenheilkd; 2006 Sep; 223(9):752-6. PubMed ID: 16986086 [TBL] [Abstract][Full Text] [Related]
5. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737 [TBL] [Abstract][Full Text] [Related]
6. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience]. Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382 [TBL] [Abstract][Full Text] [Related]
7. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Ferrara N; Damico L; Shams N; Lowman H; Kim R Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284 [TBL] [Abstract][Full Text] [Related]
8. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270 [TBL] [Abstract][Full Text] [Related]
10. [Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study]. Baeteman C; Hoffart L; Galland F; Ridings B; Conrath J J Fr Ophtalmol; 2009 May; 32(5):309-13. PubMed ID: 19769866 [TBL] [Abstract][Full Text] [Related]
11. [The results of wet AMD treatment by intravitreal injections--preliminary report]. Okruszko A; Borucka AI; Ulińska M; Szaflik J Klin Oczna; 2007; 109(10-12):389-93. PubMed ID: 18488380 [TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Brown DM; Regillo CD Am J Ophthalmol; 2007 Oct; 144(4):627-37. PubMed ID: 17893015 [TBL] [Abstract][Full Text] [Related]
13. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Kaiser PK; Blodi BA; Shapiro H; Acharya NR; Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683 [TBL] [Abstract][Full Text] [Related]
18. Ranibizumab for the treatment of neovascular AMD. Kaiser PK; Do DV Int J Clin Pract; 2007 Mar; 61(3):501-9. PubMed ID: 17313620 [TBL] [Abstract][Full Text] [Related]
19. Ranibizumab: new drug. Macular degeneration: second-line use due to risks. Prescrire Int; 2008 Feb; 17(93):3-6. PubMed ID: 18354841 [TBL] [Abstract][Full Text] [Related]